WASHINGTON, D.C. (June 8, 2006) -- The Biotechnology Industry Organization (BIO)’s VentureForum East 2006, scheduled from June 12-14 at the Hyatt Regency on the Hudson in Jersey City, NJ, will feature a series of workshops on timely issues facing emerging biotechnology company executives.
BIO VentureForum East is the largest annual East Coast regional investor conference for venture stage biotechnology and healthcare firms. It features plenary sessions and workshops on financing and partnering trends in the biotechnology industry, networking receptions, and presentations by biotech companies which have been selected by an advisory board of leading equity capital leaders.
The workshops will feature roundtable discussions among leaders in the financial and biotech industries on issues such as the effect of the rise in merger and acquisition activity on the biotech industry, the key differences and benefits of the London Stock Exchange, advice on how to execute a well-timed initial public offering, the advantages and disadvantages of the virtual biotech company model, strategies to preserve and develop intellectual property, and new opportunities and challenges in early stage financing for emerging companies.
· M&A as an Alternative Exit Strategy;
· Raising Cash and Creating Liquidity: AIM for the London Stock Exchange;
· Timing is Everything - Getting Your IPO Done Right;
· Building a Virtual Biotech Company;
· Leveraging your Intellectual Property Assets – An Executive Roundtable;
· Early Stage Funding for University and Medical Spinouts.
For more information about the program for BIO VentureForum East, please visit http://bvf-east.bio.org/opencms/bvfeast/2006/program/index.jsp .
Registration is complimentary for credentialed members of the news media. Reporters and editors working full-time for print or broadcast news organizations may register onsite with valid media credentials.
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and 31 other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products.